A detailed history of Schonfeld Strategic Advisors LLC transactions in Liquidia Corp stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 54,475 shares of LQDA stock, worth $580,158. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,475
Previous 64,635 15.72%
Holding current value
$580,158
Previous $775,000 29.81%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.9 - $14.11 $90,424 - $143,357
-10,160 Reduced 15.72%
54,475 $544,000
Q2 2024

Aug 14, 2024

BUY
$11.96 - $15.71 $773,034 - $1.02 Million
64,635 New
64,635 $775,000
Q4 2023

Feb 14, 2024

BUY
$5.77 - $12.19 $38,266 - $80,844
6,632 Added 21.98%
36,800 $442,000
Q3 2023

Nov 14, 2023

SELL
$6.27 - $8.15 $995,876 - $1.29 Million
-158,832 Reduced 84.04%
30,168 $191,000
Q2 2023

Aug 14, 2023

SELL
$6.63 - $9.9 $64,974 - $97,020
-9,800 Reduced 4.93%
189,000 $1.48 Million
Q1 2023

May 15, 2023

BUY
$5.72 - $7.91 $136,136 - $188,258
23,800 Added 13.6%
198,800 $1.37 Million
Q4 2022

Feb 14, 2023

BUY
$4.68 - $6.54 $347,256 - $485,268
74,200 Added 73.61%
175,000 $1.11 Million
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $243,569 - $547,867
65,300 Added 183.94%
100,800 $549,000
Q2 2022

Aug 15, 2022

SELL
$3.37 - $7.55 $16,176 - $36,240
-4,800 Reduced 11.91%
35,500 $155,000
Q1 2022

May 16, 2022

BUY
$5.14 - $7.38 $76,586 - $109,962
14,900 Added 58.66%
40,300 $289,000
Q4 2021

Feb 14, 2022

BUY
$2.71 - $5.17 $542 - $1,034
200 Added 0.79%
25,400 $124,000
Q3 2021

Nov 16, 2021

BUY
$2.28 - $2.95 $8,436 - $10,915
3,700 Added 17.21%
25,200 $69,000
Q2 2021

Aug 16, 2021

BUY
$2.51 - $3.11 $53,964 - $66,865
21,500 New
21,500 $61,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $685M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.